198 filings
Page 8 of 10
CORRESP
IMAB
I-Mab
1 Dec 20
Correspondence with SEC
12:00am
6-K
IMAB
I-Mab
13 Nov 20
Current report (foreign)
4:02pm
6-K
IMAB
I-Mab
12 Nov 20
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody
6:06am
6-K
IMAB
I-Mab
10 Nov 20
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting
6:19am
6-K
IMAB
I-Mab
5 Oct 20
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of
6:04am
6-K
IMAB
I-Mab
22 Sep 20
I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma
6:05am
SC 13G
IMAB
I-Mab
21 Sep 20
I-Mab / GIC Private ownership change
4:08pm
6-K
IMAB
I-Mab
17 Sep 20
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
4:04pm
6-K
IMAB
I-Mab
17 Sep 20
Current report (foreign)
4:01pm
SC 13D
IMAB
I-Mab
14 Sep 20
I-Mab / HILLHOUSE CAPITAL ADVISORS ownership change
5:19pm
6-K
IMAB
I-Mab
4 Sep 20
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
7:03am
6-K
IMAB
I-Mab
4 Sep 20
Current report (foreign)
7:02am
6-K
IMAB
I-Mab
1 Sep 20
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update
6:10am
6-K
IMAB
I-Mab
18 Aug 20
I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China
6:06am
6-K
IMAB
I-Mab
5 Aug 20
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency
6:07am
6-K
IMAB
I-Mab
29 Jul 20
I-Mab Drives Commercialization Strategy with Appointment
6:13am
6-K
IMAB
I-Mab
15 Jul 20
I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million
4:51pm
S-8
IMAB
I-Mab
15 Jul 20
Registration of securities for employees
4:04pm
6-K
IMAB
I-Mab
15 Jun 20
I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific
6:15am
6-K
IMAB
I-Mab
28 May 20
I-Mab Reports Interim Results from Part 1 Study forAnti-GM-CSF Antibody TJM2 to Treat
6:22am